Atea Pharmaceuticals Inc. (AVIR)
2.92
-0.11 (-3.63%)
At close: Mar 03, 2025, 3:59 PM
2.90
-0.68%
After-hours: Mar 03, 2025, 07:14 PM EST
No 1D chart data available
| Bid | 2.8 |
| Market Cap | 246.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -174.09M |
| EPS (ttm) | -2.07 |
| PE Ratio (ttm) | -1.41 |
| Forward PE | -1.96 |
| Analyst | Hold |
| Ask | 3.1 |
| Volume | 222,742 |
| Avg. Volume (20D) | 443,210 |
| Open | 3.03 |
| Previous Close | 3.03 |
| Day's Range | 2.88 - 3.03 |
| 52-Week Range | 2.75 - 4.48 |
| Beta | 0.18 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 30, 2020
Employees 75
Stock Exchange NASDAQ
Ticker Symbol AVIR
Website https://ateapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for AVIR stock is "Hold." The 12-month stock price forecast is $6.88, which is an increase of 135.62% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
